Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

Marie Skłodowska-Curie Action · Ended early

IMMUNOPREVENT Leveraging the immune system for breast cancer prevention

Coordinator
Fundacio Institut Hospital Del Mar D Investigacions Mediques, Spain
Runs
1 September 2025 to 31 August 2027
Status
Ended early
EU funding
€210k
Total cost
—
Partners
1 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101203857

What the project is doing

In the project's own words, from its summary on CORDIS.

Damaged cells, including precancerous cells, continuously accumulate in healthy tissues, but they are identified and eliminated by the immune system in a continuous process named immunosurveillance. Therefore, effective immunosurveillance plays an essential role in preventing cancer development. IMMUNOPREVENT aims to understand how aberrant precursor breast cancer cells escape from immune surveillance, and whether we can leverage this knowledge for future cancer prevention strategies for women at high risk of developing breast cancer.

Mutations in the DNA repair genes BRCA1 and BRCA2 confer a 70% lifetime risk of breast cancer, in contrast to the 13% risk in the general female population. The majority of BRCA mutations are inherited, but there are no effective breast cancer prevention options for BRCA carriers besides the invasive prophylactic mastectomy. Therefore, this is an unmet clinical need that demands new knowledge that can be translated into prevention strategies in the future.

In this project, I will investigate the potential tumour protective role of LCOR in clearing BRCA-deficient cancer-initiating cells before tumour establishment. LCOR enhances tumour immunogenicity by inducing tumour antigen presentation, thus rendering breast cancer cells visible and vulnerable to immune attack. However, its role in early oncogenesis remains unknown. Here, employing a novel mouse model for mammary gland-specific loss of Lcor and Brca1, I will interrogate the role of LCOR in premalignant clonal dynamics, tumour development and early immune evasion.

This knowledge will expand our general understanding of the early immune-mediated events in the premalignant mammary gland that eventually lead to cancer initiation. With this fellowship I will gain skills and knowledge on immune oncology and the results generated will be the foundation for future research lines on immunotherapy for breast cancer prevention that I will pursue as an independent researcher.

Topics

Who is involved

OrganisationCityCountryRole
Fundacio Institut Hospital Del Mar D Investigacions MediquesBarcelonaSpainCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI